New multidisciplinary prostate bone metastases clinic: First of its kind in Canada

Current Oncology

Volumn 14, Issue 1, 2007, Pages 9-12

  Goh, Philiz ^c   Harris, Kristin ^c   Napolskikh, Julie ^c   Chow, Edward ^c   Sinclair, Emily ^c   Emmenegger, Urban ^c   Lemon, Sharon ^c   Yee, Albert ^c   Wynnychuk, Lesia ^c   Myers, Jeff ^c   Danjoux, Cyril ^c   Ko, Yoo Joung ^a   Sagar, Stephen M ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE

Author keywords

Bisphosphonate; Bone metastases; Hormone refractory; Multidisciplinary; Prostate; Prostate clinic; Skeletal related events; Toronto Sunnybrook Regional Cancer Centre; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; MITOXANTRONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; PREDNISONE; STEROID; TAXANE DERIVATIVE; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BONE PAIN; CANADA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; INTERVENTIONAL RADIOLOGY; MALE; ORTHOPEDIC SURGERY; PATIENT CARE; PROSTATE CANCER; PROSTATE SURGERY;

EID: 43549088416     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.101     Document Type: Article

References (28)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 2005. Toronto: National Cancer Institute of Canada; 2005.
2. Saad F, Karakiewicz P, Perrotte P. The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol 2005;23: 14-18.
3. Coxon JP, Oades GM, Colston KW, Kirby RS. Advances in the use of bisphosphonates in the prostate cancer setting. Prostate Cancer Prostatic Dis 2004;7:99-104.
4. Coleman R, Neville-Webbe H. Prevention of bone metastases. In: Jasmin C, Coleman R, Coia L, Capanna R, Saillant G, eds. Textbook of Bone Metastases. Mississauga, ON: Wiley; 2005: 387-96.
5. Brown J, Neville-Webbe H, Coleman R. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;11:207-24.
6. Rabbani S, Shukeir N, Mazar A. Prostate cancer: models for developing novel therapeutic approaches. In: Singh G, Orr W, eds. Bone Metastasis and Molecular Mechanisms Pathophysiology. Dordrecht: Kluwer Academic Publishers; 2004: 163-86.
7. Hoskin P, Makin W. Oncology for Palliative Medicine. New York: Oxford University Press; 2003: 271-89.
8. Heidenreich A. Bisphosphonates in the management of metastatic prostate cancer. Oncology 2003;65(suppl 1):5-11.
9. Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone 1992;13(suppl 1):S57-62.
10. Bilezikian J. Management of acute hypercalcemia. N Engl J Med 1992;326:1196-203.
11. Orr F, Kostenuik P, Sanchez-Sweatman O, Singh G. Mechanisms involved in the metastasis of cancer to bone. Breast Cancer Res Treat 1993;25:151-63.
12. Tazi H, Manunta A, Rodriguez A, et al. Spinal cord compression in metastatic prostate cancer. Eur Urol 2003;44:527-32.
13. MacKenzie M, Major P. The role of bisphosphonates in bone metastasis. In: Singh G, Orr W, eds. Bone Metastasis and Molecular Mechanisms Pathophysiology. Dordrecht: Kluwer Academic Publishers; 2004: 277-301.
14. McDuffee L, Colterjohn N, Singh G. Bone metastasis and pathological fractures: bone tissue engineering as a novel therapy. In: Singh G, Rubbani S, eds. Bone Metastasis: Experimental and Clinical Therapeutics. Totowa, NJ: Humana Press; 2005: 229-41.
15. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis for prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:1373-8.
16. Chow E, Wu J, Barnes E. Radiation treatment of bone metastases. In: Singh G, Rubbani S. eds. Bone Metastasis. Experimental and Clinical Therapeutics. Totowa, NJ: Humana Press; 2005: 323-36.
17. Hoskin P, Makin W. Oncology for Palliative Medicine. New York: Oxford University Press; 2003: 31-6.
18. Coleman R. Use in prostate cancer. In: Jasmin C, Coleman R, Coia L, Capanna R, Saillant G, eds. Textbook of Bone Metastases. Mississauga, ON: Wiley; 2005: 377-84.
19. Fusi A, Procopio G, Della Torre S, et al. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 2004;90:535-46.
20. Hoskin P, Makin W. Oncology for Palliative Medicine. New York: Oxford University Press; 2003: 51-65.
21. Joly F, Tannock I. Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol 2004;15:1582-4.
22. Tannock I, Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
23. Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351: 1513-20.
24. Ernst D, Tannock I, Winquist E, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-42.
25. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with prostate cancer. J Clin Oncol 2003;21: 4277-84.
26. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005;96:964-9.
27. Saad F, Gleason D, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
28. Taylor G, Kurent J. A Clinician's Guide to Palliative Care. Boston, MA: Blackwel Science Publishing Inc.; 2003.